Enhanced oral bioavailability of levormeloxifene and raloxifene by nanoemulsion: simultaneous bioanalysis using liquid chromatography-tandem mass spectrometry

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Anthamatten A, Parish A. Clinical update on osteoporosis. J. Midwifery Womens Health 64(3), 265–275 (2019).
  MedlineGoogle Scholar
• 2. Mulder JE, Kolatkar NS, LeBoff MS. Drug insight: existing and emerging therapies for osteoporosis. Nat. Clin. Pract. Endocrinol. Metab. 2(12), 670–680 (2006).
  Medline CASGoogle Scholar
• 3. Brown JP. Long-term treatment of postmenopausal osteoporosis. Endocrinol. Metab. (Seoul) 36(3), 544–552 (2021).
  Medline CASGoogle Scholar
• 4. Epstein S. Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin. Ther. 28(2) 151–173 (2006). •• Describes advanced options for the treatment of postmenopausal osteoporosis.
  Medline CASGoogle Scholar
• 5. Goldstein SR, Nanavati N. Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study. Am. J. Obstet. Gynecol. 187(3), 521–527 (2002).
  Medline CASGoogle Scholar
• 6. Chauhan D, Yadav PK, Sultana N et al. Simultaneous estimation of raloxifene and cladrin by HPLC: application to metabolic stability studies in different species. Bioanalysis 15(11) 601–620 (2023). • Describes the simultaneous estimation of raloxifene and cladrin using high-performance liquid chromatography (HPLC).
  Medline CASGoogle Scholar
• 7. Gennari L, Merlotti D, Nuti R. Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene. Clin. Interv. Aging 5(1), 19–29 (2010). •• Selective estrogen receptor modulators used for the treatment of osteoporosis in postmenopausal women.
  Medline CASGoogle Scholar
• 8. Ning N, Lin G, Lue TF, Lin C. Effects of estrogen, raloxifene, and levormeloxifene on the expression of Rho-kinase signaling molecules in urethral smooth muscle cells. Urology 76(6), 1517.e6–1517.e11 (2010).
  MedlineGoogle Scholar
• 9. Chauhan D, Sultana N, Yadav PK et al. Pharmacokinetic interaction potential assessment of cladrin, a potent bioactive constituent of Butea monosperma, and raloxifene, a prescription anti-osteoporotic by in vitro ADME approach. Indian J. Tradit. Knowl. 21(4), 789–796 (2022). •• Describes the in vitro absorption, distribution, metabolism and excretion profile of antiosteoporotic agents.
  Google Scholar
• 10. Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. Menopause 28(9), 973–997 (2021).
  MedlineGoogle Scholar
• 11. Hotchkiss CE, Stavisky R, Nowak J, Brommage R, Lees CJ, Kaplan J. Levormeloxifene prevents increased bone turnover and vertebral bone loss following ovariectomy in cynomolgus monkeys. Bone 29(1), 7–15 (2001).
  Medline CASGoogle Scholar
• 12. Chauhan D, Dadge S, Yadav PK et al. LC–MS/MS method for simultaneous estimation of raloxifene, cladrin in rat plasma: application in pharmacokinetic studies. Bioanalysis 16(3), 141–153 (2024).
  Medline CASGoogle Scholar
• 13. Hong S, Chang J, Jeong K, Lee W. Raloxifene as a treatment option for viral infections. J. Microbiol. 59(2), 124–131 (2021).
  Medline CASGoogle Scholar
• 14. Cranney A, Adachi JD. Benefit–risk assessment of raloxifene in postmenopausal osteoporosis. Drug Saf. 28(8), 721–730 (2005).
  Medline CASGoogle Scholar
• 15. Li H, Xiao H, Lin L et al. Drug design targeting protein–protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface. J. Med. Chem. 57(3), 632–641 (2014). • Study explaining the protein interaction by using multiple ligand simultaneous docking and also describing the discovery of raloxifene and bazedoxifene.
  Medline CASGoogle Scholar
• 16. Skrumsager BK, Kiehr B, Pedersen PC, Gerrits M, Watson N, Bjarnason K. Levormeloxifene: safety, pharmacodynamics and pharmacokinetics in healthy postmenopausal women following single and multiple doses of a new selective oestrogen receptor modulator. Br. J. Clin. Pharmacol. 53(3), 284–295 (2002). •• Levormeloxifene used as a new selective estrogen receptor modulator in postmenopausal women.
  Medline CASGoogle Scholar
• 17. Pinkerton JV, Conner EA. Beyond estrogen: advances in tissue selective estrogen complexes and selective estrogen receptor modulators. Climacteric 22(2), 140–147 (2019).
  Medline CASGoogle Scholar
• 18. Veenman L. Raloxifene as treatment for various types of brain injuries and neurodegenerative diseases: a good start. Int. J. Mol. Sci. 21(20), 1–31 (2020).
  Google Scholar
• 19. Lee WL, Cheng MH, Tarng DC, Yang WC, Lee FK, Wang PH. The benefits of estrogen or selective estrogen receptor modulator on kidney and its related disease – chronic kidney disease – mineral and bone disorder: osteoporosis. J. Chin. Med. Assoc. 76(7), 365–371 (2013).
  Medline CASGoogle Scholar
• 20. Levin VA, Jiang X, Kagan R. Estrogen therapy for osteoporosis in the modern era. Osteoporos. Int. 29(5), 1049–1055 (2018).
  Medline CASGoogle Scholar
• 21. Rozenberg S, Al-Daghri N, Aubertin-Leheudre M et al. Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis? Osteoporos. Int. 31(12), 2271–2286 (2020).
  Medline CASGoogle Scholar
• 22. Mountfield RJ, Kiehr B, John BA. Metabolism, disposition, excretion, and pharmacokinetics of levormeloxifene, a selective estrogen receptor modulator, in the rat. Drug Metab. Dispos. 28(5), 503–513 (2000).
  Medline CASGoogle Scholar
• 23. Delmas PD, Bjarnason NH, Mitlak BH et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337(23), 1641–1647 (1997).
  Medline CASGoogle Scholar
• 24. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Harper KD. Raloxifene and cardiovascular events in osteoporotic postmenopausal women. JAMA 287(0607), 847–857 (2015).
  Google Scholar
• 25. Holm P, Shalmi M, Korsgaard N, Guldhammer B, Skouby SO, Stender S. A partial estrogen receptor agonist with strong antiatherogenic properties without noticeable effect on reproductive tissue in cholesterol-fed female and male rabbits. Arterioscler. Thromb. Vasc. Biol. 17(10), 2264–2272 (1997).
  Medline CASGoogle Scholar
• 26. Alexandersen P, Riis BJ, Stakkestad JA, Delmas PD. Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy. J. Clin. Endocrinol. Metab. 86(2), 755–760 (2015).
  Google Scholar
• 27. Trontelj J, Bogataj M, Marc J, Mrhar A. Development and validation of a liquid chromatography–tandem mass spectrometry assay for determination of raloxifene and its metabolites in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 855(2), 220–227 (2007).
  Medline CASGoogle Scholar
• 28. Du T, Sun R, Li L et al. Development and validation of ultra-high-performance liquid chromatography–mass spectrometry method for the determination of raloxifene and its phase II metabolites in plasma: application to pharmacokinetic studies in rats. J. Sep. Sci. 43(24), 4414–4423 (2020).
  Medline CASGoogle Scholar
• 29. Murthy A, Ravi PR, Kathuria H, Malekar S. Oral bioavailability enhancement of raloxifene with nanostructured lipid carriers. Nanomaterials 10(6), 1–17 (2020).
  Google Scholar
• 30. Kadian N, Raju KSR, Rashid M, Malik MY, Taneja I, Wahajuddin M. Comparative assessment of bioanalytical method validation guidelines for pharmaceutical industry. J. Pharm. Biomed. Anal. 126, 83–97 (2016). •• Discusses the guidelines for bioanalytical method validation.
  Medline CASGoogle Scholar
• 31. Mpanyakavili AL, Mwankuna CJ, Mabiki FP, Styrishave B. LC–MS/MS method for determination of non-opioid analgesics adulterants in herbal medicines. Chem. Afr. 5(6), 2149–2162 (2022).
  CASGoogle Scholar
• 32. Sanap SN, Agrawal S, Biswas A et al. Simultaneous assessment of ciprofloxacin and dexamethasone in ocular tear fluid by LC–MS/MS: application to a pharmacokinetic study in rabbits. Chin. J. Analyt. Chem. 51(6), 100197 (2023).
  Google Scholar
• 33. Valicherla GR, Tripathi P, Singh SK et al. Pharmacokinetics and bioavailability assessment of miltefosine in rats using high performance liquid chromatography tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 1031, 123–130 (2016). • Describes the pharmacokinetic profile of miltefosine in rats using liquid chromatography-tandem mass spectrometry (LC–MS/MS).
  Medline CASGoogle Scholar
• 34. Van Eeckhaut A, Lanckmans K, Sarre S, Smolders I, Michotte Y. Validation of bioanalytical LC–MS/MS assays: evaluation of matrix effects. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877(23), 2198–2207 (2009).
  Medline CASGoogle Scholar
• 35. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC–MS/MS. Anal. Chem. 75(13), 3019–3030 (2003).
  Medline CASGoogle Scholar
• 36. Ahmed S, Gull A, Alam M, Aqil M, Sultana Y. Ultrasonically tailored, chemically engineered and ‘quality by design’ enabled fabrication of agomelatine nanoemulsion; optimization, characterization, ex-vivo permeation and stability study. Ultrason. Sonochem. 41, 213–226 (2018). • Study describing the quality-by-design approach for the optimization of nanoformulations.
  Medline CASGoogle Scholar
• 37. Singh Y, Ojha P, Srivastava M, Chourasia MK. Reinvestigating nanoprecipitation via Box–Behnken design: a systematic approach. J. Microencapsulation 32(1), 75–85 (2015).
  Medline CASGoogle Scholar
• 38. Pawar VK, Panchal SB, Singh Y et al. Immunotherapeutic vitamin E nanoemulsion synergies the antiproliferative activity of paclitaxel in breast cancer cells via modulating Th1 and Th2 immune response. J. Control. Rel. 196, 295–306 (2014).
  Medline CASGoogle Scholar
• 39. Sharif HR, Abbas S, Majeed H et al. Formulation, characterization and antimicrobial properties of black cumin essential oil nanoemulsions stabilized by OSA starch. J. Food Sci. Technol. 54(10), 3358–3365 (2017).
  Medline CASGoogle Scholar
• 40. Mahadev M, Nandini HS, Ramu R et al. Fabrication and evaluation of quercetin nanoemulsion: a delivery system with improved bioavailability and therapeutic efficacy in diabetes mellitus. Pharmaceuticals 15(1), 70 (2022).
  Medline CASGoogle Scholar
• 41. Wang W, Xi M, Duan X, Wang Y, Kong FE. Delivery of baicalein and paclitaxel using self-assembled nanoparticles: synergistic antitumor effect in vitro and in vivo. Int. J. Nanomed. 10, 3737–3750 (2015).
  Medline CASGoogle Scholar
• 42. Yadav PK, Tiwari AK, Saklani R et al. HPLC method for simultaneous estimation of paclitaxel and baicalein: pharmaceutical and pharmacokinetic applications. Bioanalysis 14(14), 1005–1020 (2022). •• Simultaneous estimation of paclitaxel and baicalein using HPLC and its applicability in pharmacokinetic studies.
  Medline CASGoogle Scholar
• 43. Elsheikh MA, Elnaggar YSR, Gohar EY, Abdallah OY. Nanoemulsion liquid preconcentrates for raloxifene hydrochloride: optimization and in vivo appraisal. Int. J. Nanomed. 7, 3787–3802 (2012).
  Medline CASGoogle Scholar
• 44. Meher JG, Dixit S, Singh Y et al. Paclitaxel-loaded colloidal silica and TPGS-based solid self-emulsifying system interferes Akt/mTOR Pathway in MDA-MB-231 and demonstrates anti-tumor effect in syngeneic mammary tumors. AAPS PharmSciTech 21(8), 1–18 (2020).
  Google Scholar
• 45. Kim JE, Park YJ. Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer. Int. J. Nanomed. 12, 645–658 (2017).
  Medline CASGoogle Scholar
• 46. Yadav PK, Saklani R, Tiwari AK et al. Ratiometric codelivery of paclitaxel and baicalein loaded nanoemulsion for enhancement of breast cancer treatment. Int. J. Pharm. 643(3), 123209 (2023).
  Medline CASGoogle Scholar
• 47. Yadav PK, Saklani R, Tiwari AK et al. Enhanced apoptosis and mitochondrial cell death by paclitaxel-loaded TPP-TPGS1000-functionalized nanoemulsion. Nanomedicine 18(4), 343–366 (2023). • Study describing the codelivery of paclitaxel- and baicalein-loaded nanoemulsion for the treatment of breast cancer.
  CASGoogle Scholar
• 48. Chen Y, Jia X, Chen J, Wang J, Hu M. The pharmacokinetics of raloxifene and its interaction with apigenin in rat. Molecules 15(11), 8478–8487 (2010).
  Medline CASGoogle Scholar
• 49. Mishra R, Tiwari A, Bhadauria S, Mishra J, Murthy PK, Murthy PSR. Therapeutic effect of centchroman alone and in combination with glycine soya on 7,12-dimethylbenz[α]anthracene-induced breast tumor in rat. Food Chem. Toxicol. 48(6), 1587–1591 (2010).
  Medline CASGoogle Scholar